Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27567759 | 0.85 | GNAI3 (0.36) | GNAI3GNAO1GNAI1KDM4EALDH1A1 | |
| SCHEMBL18980322 | 0.81 | KDM4E (0.36) | ITGB3ITGA2BKDM4EALDH1A1SLC6A9 | |
| SCHEMBL5132272 | 0.81 | ALDH1A1 (0.47) | KDM4EALDH1A1SLC6A9HRH3MEN1 | |
| SCHEMBL7744888 | 0.79 | SLC6A9 (0.40) | KDM4EALDH1A1SLC6A9KCNH2HRH3 | |
| SCHEMBL14100030 | 0.79 | SLC6A9 (0.40) | KDM4EALDH1A1SLC6A9KCNH2HRH3 | |
| SCHEMBL24220960 | 0.79 | SLC6A9 (0.40) | KDM4EALDH1A1SLC6A9KCNH2HRH3 | |
| SCHEMBL29299508 | 0.79 | SLC6A9 (0.40) | KDM4EALDH1A1SLC6A9KCNH2HRH3 | |
| SCHEMBL13223389 | 0.79 | SLC6A9 (0.40) | KDM4EALDH1A1SLC6A9KCNH2HRH3 | |
| SCHEMBL1133814 | 0.79 | — | — | |
| SCHEMBL3967181 | 0.79 | SLC6A9 (0.40) | KDM4EALDH1A1SLC6A9KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1291346-B1 | Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORP (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-0708768-B1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1291346-A1 | Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020188122-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2002-12-12 | — | — | US | disclosed |
| EP-1229035-A1 | Imine intermediates for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1227091-A2 | Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1227092-A2 | Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6222036-B1 | REACTING 2-THIO-4-DIMETHYOXYMETHYL-PYRIMIDINE WITH ACETIC ACID AND CATALYTIC AMOUNT OF CONCETRATED SULFURIC ACID TO PRODUCE 2-THIOPYRIMIDINE ALDEHYDE | SMITHKLINE BEECHAM CORPORATION | 2001-04-24 | — | — | US | disclosed |
| US-6150557-A | REACTING COMPOUND CONTAINING SECONDARY AMIDE GROUPS WITH BENZENESULFINIC ACID OR ITS DERIVATIVE IN PRESENCE OF ACID CATALYST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-21 | — | — | US | disclosed |
| US-6103936-A | REACTING ALDEHYDE, SULFIDE, SULFONE, OR SULFOXIDE WITH FORMAMIDE IN PRESENCE OF ACID CATALYST, AND OPTIONALLY A DEHYDRATING AGENT | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0270947-B1 | SUBSTITUTED BASIC 2-AMINOTETRALINES | BAYER AG (DE) | 1993-05-19 | — | — | EP | disclosed |
| US-5153225-A | For treating disorders of the central nervous system, cardiovascular system and intestinal tract | BAYER AKTIENGESELLSCHAFT (DE) | 1992-10-06 | — | — | US | disclosed |
| US-5137901-A | For binding 5-HT 1 receptors; treating central nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | disclosed |
| US-5026857-A | Cetnral nervous system disorders; antiserotonine agent | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-25 | — | — | US | disclosed |
| US-5021438-A | Having affinity for 5-hydroxytryptamine receptors; treating central nervous system and cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-04 | — | — | US | disclosed |
| CN-1039809-A | The aminomethyl tetraline that replaces and the preparation of heterocycle homologue thereof | BAYER AG (DE) | 1990-02-21 | — | — | CN | disclosed |
| EP-0352613-A2 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1990-01-31 | — | — | EP | disclosed |
| US-4880802-A | CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1989-11-14 | — | — | US | disclosed |
| CN-1036566-A | 1,3,4,5-tetrahydro benzo [c, d] diindyl compounds | BAYER AG (DE) | 1989-10-25 | — | — | CN | disclosed |
| EP-0270947-A2 | Substituted basic 2-aminotetralines | BAYER AG (DE) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188122-A1 | Novel compounds | IL2, IFNG, IL1RN | ITGB3 1100/4885ITGA2B 756/4885GNAI3 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.